Aryl ether substituted imidazoquinolines

Details Aryl ether substituted imidazoquinolines Aryl ether substituted imidazoquinolines

2005-10-11

2005-10-11

Huang, Evelyn Mei (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S082000, C546S084000, C546S159000

Reexamination Certificate

active

06953804

ABSTRACT:
Imidazoquinoline and tetrahydroimidazoquinoline compounds that contain ether and aryl or alkenyl functionality at the 1-position are useful as immune response modifiers. The compounds and compositions of the invention can induce the biosynthesis of various cytokines and are useful in the treatment of a variety of conditions including viral diseases and neoplastic diseases.

REFERENCES:
patent: 3314941 (1967-04-01), Littell et al.
patent: 4689338 (1987-08-01), Gerster
patent: 4698348 (1987-10-01), Gerster
patent: 4929624 (1990-05-01), Gerster et al.
patent: 4988815 (1991-01-01), Andre et al.
patent: 5037986 (1991-08-01), Gerster
patent: 5175296 (1992-12-01), Gerster
patent: 5238944 (1993-08-01), Wick et al.
patent: 5266575 (1993-11-01), Gerster
patent: 5268376 (1993-12-01), Gerster
patent: 5346905 (1994-09-01), Gerster
patent: 5352784 (1994-10-01), Nikolaides et al.
patent: 5367076 (1994-11-01), Gerster
patent: 5389640 (1995-02-01), Gerster et al.
patent: 5395937 (1995-03-01), Nikolaides et al.
patent: 5446153 (1995-08-01), Lindstrom et al.
patent: 5482936 (1996-01-01), Lindstrom
patent: 5693811 (1997-12-01), Lindstrom
patent: 5741908 (1998-04-01), Gerster et al.
patent: 5756747 (1998-05-01), Gerster et al.
patent: 5939090 (1999-08-01), Beaurline et al.
patent: 6039969 (2000-03-01), Tomai et al.
patent: 6069149 (2000-05-01), Nanba et al.
patent: 6083505 (2000-07-01), Miller et al.
patent: 6110929 (2000-08-01), Gerster et al.
patent: 6194425 (2001-02-01), Gerster et al.
patent: 6245776 (2001-06-01), Skwierczynski et al.
patent: 6331539 (2001-12-01), Crooks et al.
patent: 6376669 (2002-04-01), Rice et al.
patent: 6451810 (2002-09-01), Coleman et al.
patent: 6518265 (2003-02-01), Kato et al.
patent: 6525064 (2003-02-01), Dellaria et al.
patent: 6541485 (2003-04-01), Crooks et al.
patent: 6545016 (2003-04-01), Dellaria et al.
patent: 6545017 (2003-04-01), Dellaria et al.
patent: 6558951 (2003-05-01), Tomai et al.
patent: 6573273 (2003-06-01), Crooks et al.
patent: 6656938 (2003-12-01), Crooks et al.
patent: 6660735 (2003-12-01), Crooks et al.
patent: 6664264 (2003-12-01), Dellaria et al.
patent: 6664265 (2003-12-01), Crooks et al.
patent: 6667312 (2003-12-01), Bonk et al.
patent: 2002/0055517 (2002-05-01), Smith
patent: 2002/0058674 (2002-05-01), Hedenstrom et al.
patent: 0 394 026 (1990-10-01), None
patent: 1 104 764 (2001-06-01), None
patent: 9-208584 (1997-08-01), None
patent: 9-255926 (1999-03-01), None
patent: 11-222432 (1999-08-01), None
patent: 2000-247884 (2000-09-01), None
patent: WO 01/74343 (2001-10-01), None
patent: WO 02/36592 (2002-05-01), None
patent: WO 02/46188 (2002-06-01), None
patent: WO 02/46189 (2002-06-01), None
patent: WO 02/46190 (2002-06-01), None
patent: WO 02/46193 (2002-06-01), None
patent: WO 02/46749 (2002-06-01), None
patent: WO 02/102377 (2002-12-01), None
patent: WO 03/020889 (2003-03-01), None
patent: WO 03/043572 (2003-05-01), None
patent: WO 03/045391 (2003-06-01), None
Sof'ina et al. Experimental Evaluation of Antitumor Drugs in the USA and USSR and Clinical Correlations. NCI Monograph 55. NIH Publication No. 80-1933 (1980), pp. 76-78.
Strandtmann et al. J. Med. Chem. (1967), 10(6):1063-1065.
Wozniak, et al, “The Amination of 3-nitro-1,5-naphthyridines by Liquid Ammonia/Potassium Permanganate1,2. A New and Convenient Amination Method.”,Journal of the Royal Netherlands Chemical Society, 102, pp 511-513, Dec. 12, 1983.
Brennan, et al, “Automated Bioassay of Interferons in Micro-test Plates”,Biotechniques,Jun./Jul., 78, 1983.
Testerman, et al., “Cytokine Induction by the Immunomodulators Imiquimod and S-27609”,Journal of Leukocyte Biology,vol. 58, pp. 365-372, Sep. 1995.
Bachman, et al, “Synthesis of Substituted Quinolylamines. Derivatives of 4-Amino-7-Chloroquinoline”,J. Org. Chem,15, pp 1278-1284 (1950).
Jain, et al, “Chemical and Pharmacological Investigations of Some ω-Substituted Alkylamino-3-aminopyridines”,J. Med. Chem.,11, pp 87-92 (1968).
Baranov, et al.,Chem. Abs.85, 94362, (1976).
Berényi, et al, “Ring Transformation of Condensed Dihydro-as-triazines”,J. Heterocyclic Chem.,18, pp 1537-1540 (1981).
Chollet, et al, “Development of a Topically Active Imiquimod Formulation”,Pharmaceutical Development and Technology,4(1), pp 35-43 (1999).
Izumi, et al., “1H-Imidazo[4,5-c]quinoline Derivatives as Novel Potent TNF-α Suppressors: Synthesis and Structure-Activity Relationship of 1-, 2- and 4-Substituted 1H-imidazo[4,5-c]pyridines”,Bioorganic&Medicinal Chemistry,11 pp 2541-2550 (2003).
Sidky etal., “Inhibition of Murine Tumor Growth by an Interferon-inducing Imidazoquinolinamine”,Cancer Research,52, 3528-3533, Jul. 1, 1992.
R.L. Miller et al., “Imiquimod applied topically: a novel immune response modifier and new class of drug”,International Journal of Immunopharmacology,21, 1-14 (1999).
Karl R. Beutner, MD, et al., “Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream”,J.Am.Acad.Dermatol.,vol. 41, No. 6, 1002-1007 (Dec. 1999).
Davis et al., “Self-Administered Topical Imiquimod Treatment of Vulvar Intraepithelial Neoplasia”,Journal of Reproductive Medicine,vol. 45, No. 8, 619-623, (Aug. 2000).
Alexander Steinmann et al., “Topical Imiquimod Treatment of a Cutaneous Melanoma Metastasis”,J.Am.Acad.Dermatol.,Letters, 555-556 (Sep. 2000).

Affiliated with

Also associated with

Rating

Aryl ether substituted imidazoquinolines does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Aryl ether substituted imidazoquinolines, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Aryl ether substituted imidazoquinolines will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3492608